A Phase 1 interventional study of Niraparib and Abiraterone Acetate (AA) in Prostatic Neoplasms, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 16 sites in 11 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing niraparib in Prostatic Neoplasms — 3 open to participants now, 7 under way, 2 of them phase 3. niraparib · Prostatic Neoplasms.
Among the 19 studies testing niraparib in Prostatic Neoplasms, this one is the 6th largest by enrollment, is one of 4 that started in 2020, is one of 6 in phase 1, and was the 11th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.
Browse Prostatic Neoplasms studies →3 of the 19 studies testing niraparib in Prostatic Neoplasms are open now, in 6 countries. Recruiting first, the newest first:
University of British Columbia · Sites in United States, Canada
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Karolinska Institutet · Sites in Belgium, Norway, Sweden and 1 more country
Ages 18+ · Men only
By country, each count listing its studies:
niraparib: first FDA approval 2017 (ZEJULA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, niraparib is the treatment under test here. Read study by study →
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 2
First in 2008; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 60 across 5,349 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 34 across the 19 interventional studies. Of the 8 that completed or were terminated, 4 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 19 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
88 studies in Prostatic Neoplasms by Johnson & Johnson: 9 open now, 23 under way, 9 of them phase 3. Of 58 finished, 24 (41%) have results posted.
Among the 88 studies in Prostatic Neoplasms by Johnson & Johnson, this one is the 26th largest by enrollment of the 68 interventional ones that give a count, is one of 7 that started in 2020, is one of 27 in phase 1, reaches primary completion later than 5 of the 22 other live ones, and was the 70th registered.
Johnson & Johnson’s Prostatic Neoplasms studies by the year they started, since 1995.
3 of the studies testing niraparib in Prostatic Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT04194554University of Michigan Rogel Cancer CenterA Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer | 2027-05 |
| NCT04812366University of British ColumbiaGenomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing niraparib in Prostatic Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 88 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths and formulations of niraparib and abiraterone acetate (AA) at steady state under modified fasted conditions in participants with metastatic castration-resistant prostate cancer (mCRPC).
Niraparib is an orally available, highly selective poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, with potent activity against PARP-1 and PARP-2 deoxyribonucleic acid (DNA)-repair polymerases. AA is a pro-drug of abiraterone which selectively inhibits the enzyme 17 alpha-hydroxylase/C17,20-lyase (CYP17), that is found in the testes and adrenals (leading to systemic inhibition of testosterone production), as well as in prostate tissues and tumors. The rationale of the study is to investigate the various strengths and formulations of niraparib and AA plus prednisone or prednisolone (P) in metastatic castration resistant prostate cancer (mCRPC) participants with and without homologous recombination repair (HRR) gene alterations. In participants with metastatic prostate cancer, DNA-repair anomalies are found in approximately 15 percent (%) to 20% of tumors. This study consists 4 periods: screening phase (up to 21 days); treatment phase (up to 22 days); extension and long-term extension phases (from day 23 until discontinuation); and post-treatment follow up phase (end of treatment [EoT] visit within 30 days after the last dose of study treatment). Total duration of study is up to 1.4 years. Efficacy, safety, pharmacokinetics (PK), and biomarkers will be assessed at specified time points during this study. Participants safety will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive single doses of niraparib and abiraterone acetate (AA) using niraparib Formulation 1 as Treatment A in Treatment Period 1, followed by multiple doses of niraparib and AA using niraparib Formulation 2 as Treatment B in Treatment Period 2, followed by multiple doses of niraparib and AA using niraparib Formulation 4 as Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AA-prednisone (AAP) or AAP alone.
Drug: Niraparib · Drug: Abiraterone Acetate (AA) · Drug: Prednisone
Participants will receive Treatment A in Treatment Period 1 followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
Drug: Niraparib · Drug: Abiraterone Acetate (AA) · Drug: Prednisone
Participants will receive single doses of niraparib and AA using niraparib Formulation 3 as Treatment C in Treatment Period 1, followed by Treatment B in Treatment Period 2, followed by Treatment D in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
Drug: Niraparib · Drug: Abiraterone Acetate (AA) · Drug: Prednisone
Participants will receive Treatment C in Treatment Period 1, followed by Treatment D in Treatment Period 2, followed by Treatment B in Treatment Period 3. From Period 2 onwards and during Extension and Long-term Extension Phases, all participants will continue to receive treatment with niraparib and AAP or AAP alone.
Drug: Niraparib · Drug: Abiraterone Acetate (AA) · Drug: Prednisone
Niraparib will be administered orally.
Abiraterone Acetate will be administered orally.
Prednisone will be administered orally.
Maximum Observed Analyte Concentration at Steady State (Cmax,ss) of Niraparib and Abiraterone Acetate (AA) [Period 2 and Period 3]
Cmax,ss is defined as maximum observed analyte concentration at steady state.
Time frame: Predose, up to 10 hour post dose
Area Under the Plasma Concentration-time Curve from Time Zero to 24 Hours at Steady State (AUC [0-24h],ss) of Niraparib and AA (Period 2 and Period 3)
AUC (0-24h),ss is defined as area under the plasma concentration-time curve from time zero to 24 hours at steady state.
Time frame: Predose, up to 24 hours post dose
Ratio of Individual Cmax,ss Values Between Test and Reference Treatment (Period 2 and Period 3)
Ratio of individual Cmax,ss values between test and reference treatment will be assessed.
Time frame: Predose, up to 10 hours post dose
Ratio of individual AUC (0-24h),ss Values Between Test and Reference Treatment (Period 2 and Period 3)
Ratio of individual AUC (0-24h),ss values between test and reference treatment will be assessed.
Time frame: Predose, up to 24 hours post dose
Maximum Observed Analyte Concentration at (Cmax) of Niraparib and AA (Period 1)
Cmax is defined as maximum observed analyte concentration.
Time frame: Predose, up to 72 hours post dose
Area Under the Plasma Concentration-time Curve from Time Zero to 72 Hours (AUC [0-72h]) of Niraparib and AA (Period 1)
AUC (0-72h) is defined as area under the plasma concentration-time curve from time zero to 72 hours post dosing.
Time frame: Predose, up to 72 hours post dose
Ratio of individual AUC (0-72h) Values Between Test and Reference Treatment (Period 1)
Ratio of individual AUC (0-72h) values between test and reference treatment will be assessed.
Time frame: Predose, up to 72 hours post dose
Serum Testosterone Level
Serum testosterone level will be assessed.
Time frame: Predose on Day -7, Day 11, Day 12 and Day 23
Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.
Time frame: From study start until study completion (up to 3.1 years)
Number of Participants with AEs by Severity
Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death.
Time frame: From study start until study completion (up to 3.1 years)
Number of Participants with Clinical Laboratory Abnormalities
Number of participants with clinical laboratory abnormalities including hematology, serum chemistry and urinalysis will be reported.
Time frame: From study start until study completion (up to 3.1 years)
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
Ran from Nov 2020 to primary completion in Oct 2021, 11 months.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 11 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Niraparib · Abiraterone Acetate
Janssen Research & Development, LLC →